These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11826461)

  • 1. [The cytochrome P-450 system].
    Spigset O
    Tidsskr Nor Laegeforen; 2001 Nov; 121(28):3296-8. PubMed ID: 11826461
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
    Andersson T; Flockhart DA; Goldstein DB; Huang SM; Kroetz DL; Milos PM; Ratain MJ; Thummel K
    Clin Pharmacol Ther; 2005 Dec; 78(6):559-81. PubMed ID: 16338273
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.
    Obach RS; Walsky RL; Venkatakrishnan K; Houston JB; Tremaine LM
    Clin Pharmacol Ther; 2005 Dec; 78(6):582-92. PubMed ID: 16338274
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical pharmacologic aspects of cytochrome P-450 dependent biotransformation of drugs].
    Ackermann E
    Pharmazie; 1978 Jul; 33(7):400-6. PubMed ID: 364493
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cytochrome P-450 isoenzymes as predictors of drug interactions].
    Pelkonen O
    Duodecim; 1994; 110(17):1575-9. PubMed ID: 7497987
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation.
    Singh G; Renton KW
    Mol Pharmacol; 1981 Nov; 20(3):681-4. PubMed ID: 6173738
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytochrome P-450: the Japanese connection.
    Gelboin HV
    Jpn J Cancer Res; 1993 Feb; 84(2):inside front cover. PubMed ID: 8463126
    [No Abstract]   [Full Text] [Related]  

  • 9. Proceedings: Enzymes catalyzing biotransformation of drugs.
    Kamataki T; Kitada M
    Jpn J Pharmacol; 1974; 24(0):s:20. PubMed ID: 4545590
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs, vitamins, and gender.
    Berg MJ
    J Gend Specif Med; 1998 Sep; 1(1):10-1. PubMed ID: 11279846
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug metabolism by the cytochrome p-450 enzyme. Variability of polymorphisms and exogenous carriers].
    Kreutzkamp B
    Med Monatsschr Pharm; 2006 Feb; 29(2):48-50. PubMed ID: 16506587
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.
    Murray M
    Drug Metab Rev; 1987; 18(1):55-81. PubMed ID: 3311684
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.
    Palatini P; Orlando R; De Martin S
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1215-30. PubMed ID: 20604736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of drug metabolizing enzymes in the effect and side-effect of the drugs].
    Vereczkey L; Jemnitz K; Monostory K; Veres Z; Kóbori L
    Orv Hetil; 2005 May; 146(19):947-52. PubMed ID: 15969306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepigenetics: its role in interindividual differences in drug response.
    Gomez A; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2009 Apr; 85(4):426-30. PubMed ID: 19242404
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolism of drugs. III. Genetic factors inducing and inhibiting metabolism].
    Dyderski S; Grzymisławski M
    Pol Merkur Lekarski; 2005 Apr; 18(106):457-61. PubMed ID: 16161934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug essentials. The cytochrome P450 microenzyme system and targeted therapies: Minimizing drug interactions.
    Wilkes GM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):33, 52-6. PubMed ID: 19856586
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: drug metabolism and pharmacogenetics.
    La Du BN
    Drug Metab Dispos; 1983; 11(4):283-5. PubMed ID: 6137331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.